直 Japanese PDF Font
  • Our Professionals
  • Our Work
  • Our Insights
  • Offices
  • Firm
  • Careers
Finnegan
  • Articles & Books
    • Ad Law Buzz Blog
    • At the PTAB Blog
    • European IP Blog
    • Federal Circuit IP Blog
    • INCONTESTABLE® Blog
    • Prosecution First Blog
  • Events & Webinars
  • IP Updates
  • Podcasts
    • AI + Finnegan
    • AI + Copyright
    • AI + Patent
    • AI + Privacy
    • AI + Trade Secrets
    • AI + Trademark
  • Unified Patent Court (UPC) Hub

European IP Blog

The Implausibility of “Plausibility” as an Evidentiary Standard at the EPO

March 24, 2023

Authored and Edited by James G. Bell; Maeve O'Flynn; Victoria A. Randall, Ph.D.

The much-anticipated decision in G2/21 issued from the Enlarged Board of Appeal (“the Board”) at the European Patent Office on 23 March 2023. Three points were referred to the Board regarding the diverging evidentiary standards of using plausibility/implausibility for technical effect determination based on evidence presented after the filing date of the application, “post-filed evidence”. The Board ultimately held that:

1) evidence provided after the effective filing date of the application and relied upon by an applicant/patentee to prove a technical effect may not be disregarded solely because the evidence was not public prior to the filing of the application; and  

2) a technical effect derivable by one of skill in the art from, and embodied by, the technical teachings of the application at time of filing may serve as a basis for an inventive step.

Critical to the Board’s decision in G2/21 was its qualification of free evaluation of evidence in assessing any means of evidence submitted as a “universally applicable principle of both procedural and substantive law” and its determination that “plausibility,” is not a distinct condition of patentability and patent validity as concerns either Articles 56 (inventive step) or 83 (sufficiency of disclosure) of the EPC.  G2/21 ¶¶ 89 and 92. 

Given these principles, the Board concluded that the relevant standard, when assessing inventive step, is what one of skill would understand to be the technical teaching of the application as of the filing date, and whether the technical effect relied upon for inventive step was encompassed in that technical teaching. Evidence demonstrating a technical effect so encompassed, even though only available after the filing date of the application, is to be taken into account when assessing inventive step.  Id. ¶¶ 93-94.

Takeaway: post-filed evidence can be used to support a technical effect, if that technical effect can be derived from the technical teaching of the application at the filing date.

Look for a more detailed analysis of this case coming soon.

Related Practices

Prosecution and Portfolio Management

Patent Drafting and Prosecution

Related Offices

London

Contacts

James G. Bell
Partner
London
+44 (0)20 7864 2824
Email
Maeve O'Flynn
Partner
London
+44 (0)20 7864 2856
Email
Victoria A. Randall, Ph.D.
Partner
London
+44 (0)20 7864 2812
Email

Copyright © 2023 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP. 


DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. One of our lawyers will be happy to discuss the possibility of representation with you. Additional disclaimer information.

Related Insights

Conference

7th International Conference on Biofuels and Bioenergy

June 25-26, 2026

Edinburgh

Conference

2026 Copyright Society Annual Meeting

June 14-16, 2026

Louisville

Reception

12th Annual Georgia Asian Pacific American Bar Association Gala

May 21, 2026

Atlanta

At the PTAB Blog

Before the Holding, the Message: Director Squires Uses Magnolia Medical to Outline PTAB Discretionary Denial Policy Changes

May 20, 2026

Conference

19th Annual Forum on Pharma & Biotech Patent Litigation in Europe

May 19-20, 2026

Amsterdam

Webinar

Changes at the PTAB from Settled Expectations to Real Parties in Interest to Director Involvement

May 18, 2026

Webinar

Conference

Best Practices and Tech in Intellectual Property Conference 2026

May 17, 2026

Tel Aviv

Seminar

IP Strategy at the Crossroads: Technology, Enforcement, and Contracts

May 15, 2026

Taipei

Articles

COPPA’s Amended Rule Is Now in Full Effect: What Operators Need to Know

May 15, 2026

Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.

  • Privacy
  • Disclaimer
  • Legal Notices
  • Fraud Alert
  • EEO Statement
  • Cookies
  • Contact Us

© 2026 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP